Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EuroPCR in Brief

This article was originally published in The Gray Sheet

Executive Summary

New clinical data from St. Jude Medical’s and Boston Scientific’s trials of renal denervation devices to treat hypertension show progress in the development of these novel blood pressure therapies, but both companies remain behind Medtronic. More news from EuroPCR, the official congress of the European Association of Percutaneous Cardiovascular Interventions.

You may also be interested in...



TAVR Evolution On Display At EuroPCR

Data on both new transcatheter aortic valve technologies and established TAVR devices were featured at this year’s EuroPCR meeting in Paris.

Medtronic Renal Denervation System Provides Durable Blood Pressure Benefits In Longest Trial To Date

The latest results from Medtronic’s SYMPLICITY HTN-2 trial show that patients treated for severe hypertension with the company’s Symplicity radio frequency renal denervation system showed a sustained reduction in blood pressure. The firm also announced the start of a renal denervation trial in patients with moderate hypertension.

Boston Scientific Plans More Job Cuts As Part Of Ongoing Restructuring

The company announced plans to reduce annual expenses by $150 to $200 million by reducing up to 1,500 positions through a combination of employee attrition and position reductions. The company also announced that Jeffrey Capello will step down as chief financial officer at the end of the year.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT032087

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel